Novo Nordisk A/S (FRA:NOV1)

Market Cap	182.10B -15.9%
Revenue (ttm)	44.06B +5.6%
Net Income	15.57B +4.8%
EPS	3.50 +5.0%
Shares Out	n/a
PE Ratio	11.69
Forward PE	15.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	11.80
Previous Close	11.70
Day's Range	11.80 - 11.90
52-Week Range	8.85 - 16.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 66,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV1

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error